Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 26, 2024

Clinical- and Genomic-Based Decision-Support System to Define the Optimal Timing of Allogeneic HSCT in Patients With Myelodysplastic Syndromes

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
J. Clin. Oncol 2024 May 09;[EPub Ahead of Print], CA Tentori, C Gregorio, M Robin, N Gagelmann, C Gurnari, S Ball, JC Caballero Berrocal, L Lanino, S D'Amico, M Spreafico, G Maggioni, E Travaglino, E Sauta, M Meggendorfer, LP Zhao, A Campagna, , V Savevski, A Santoro, N Al Ali, D Sallman, F Sole, G Garcia-Manero, U Germing, N Kroger, S Kordasti, V Santini, G Sanz, W Kern, U Platzbecker, M Diez-Campelo, JP Maciejewski, L Ades, P Fenaux, T Haferlach, AM Zeidan, G Castellani, R Komrokji, F Ieva, MG Della Porta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading